Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 513 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infection, Human Immunodeficiency Virus I Clear all
Completed Phase 1 Interventional

Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00734890
View directory record Official record
Conditions
Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bevacizumab, vandetanib, laboratory biomarker analysis, pharmacological study
Biological · Drug · Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Not applicable Interventional

An Automated, Tailored Information Application for Medication Health Literacy

NCT01304186
View directory record Official record
Conditions
Human Immunodeficiency Virus I Infection
Interventions
Tailored Information
Behavioral
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Mar 1, 2013 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC

NCT00000753
View directory record Official record
Conditions
HIV Infections
Interventions
Atevirdine mesylate, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1995
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 3 Interventional

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

NCT00044577
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
abacavir/lamivudine, abacavir, lamivudine, tenofovir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
30
States / cities
Los Angeles, California • Oakland, California • Fort Lauderdale, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma

NCT00000681
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Zidovudine, Sargramostim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

A Study of 141W94 in Combination With Other Anti-HIV Drugs

NCT00002372
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Amprenavir, Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Diego, California • San Francisco, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

NCT00376090
View directory record Official record
Conditions
HIV Infections
Interventions
MVA-CMDR, Placebo
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children Infected With or at Risk for HIV Infection

NCT00000984
View directory record Official record
Conditions
HIV Infections
Interventions
CD4 Antigens
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
San Francisco, California • Stanford, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Study of TUTI-16 in HIV-1 Infected and Uninfected Subjects

NCT01144026
View directory record Official record
Conditions
HIV Infections
Interventions
TUTI-16 (0.2mg), TUTI-16 (1.0 mg)
Biological
Lead sponsor
Thymon, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers

NCT03441984
View directory record Official record
Conditions
HIV Infections
Interventions
Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004

NCT02042248
View directory record Official record
Conditions
HIV
Interventions
AGS-004
Biological
Lead sponsor
Cynthia L Gay, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Immunogenicity Trial of IHV01

NCT02756208
View directory record Official record
Conditions
HIV Infection
Interventions
300 ug FLSC vaccine, 150 ug FLSC vaccine, 75 ug FLSC vaccine, Placebo
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients

NCT00002327
View directory record Official record
Conditions
HIV Infections, Condyloma Acuminata
Interventions
Cidofovir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Berkeley, California • San Francisco, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 13, 2026, 7:10 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV

NCT07698600
View directory record Official record
Conditions
HIV -1 Infection
Interventions
BNT168, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 50 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 2 Interventional Results available

T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents

NCT00022763
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Years to 16 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
7
States / cities
Los Angeles, California • Gainesville, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 13, 2026, 7:10 PM EDT
Completed No phase listed Observational

Charlotte Retention in Care Study

NCT03584048
View directory record Official record
Conditions
HIV I Infection
Interventions
Alert to provider
Other
Lead sponsor
Epividian
Industry
Eligibility
18 Years and older
Enrollment
6,500 participants
Timeline
2018 – 2019
U.S. locations
4
States / cities
Charlotte, North Carolina • Huntersville, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Not applicable Interventional Results available

Physiologic Growth Hormone Effects in HIV Lipodystrophy

NCT00100698
View directory record Official record
Conditions
AIDS, HIV Infections
Interventions
recombinant human growth hormone, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2010 · Synced Oct 13, 2026, 7:10 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers

NCT03878121
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Ad4-Env145NFL, Ad4-Env150KN, VRC-HIVRGP096-00-VP (Trimer 4571) with alum
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects

NCT02411435
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
CAB, RIF
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults

NCT00073216
View directory record Official record
Conditions
HIV Infections
Interventions
Clade B gag DNA/PLG and env DNA/PLG Microparticles, Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2007
U.S. locations
4
States / cities
St Louis, Missouri • Providence, Rhode Island • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 3 Interventional Results available

A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily

NCT01227824
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I
Interventions
GSK1349572 (dolutegravir), raltegravir, GSK1349572 Placebo, ABC/3TC, TDF/FTC, raltegravir Placebo
Drug · Other
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 Months

NCT00006279
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

NCT00000878
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
18
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 13, 2026, 7:10 PM EDT
Completed Phase 1 Interventional

Safety of Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine/TDF in HIV Infected Pregnant Women and Their Infants

NCT00076791
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine/Tenofovir disoproxil fumarate, Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
11
States / cities
Washington D.C., District of Columbia • Miami, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 13, 2026, 7:10 PM EDT